Auro Laboratories Limited , a pharmaceutical company based in Tarapur, Maharashtra, has reported a net loss of Rs 71.58 lakhs for the quarter ended September 30, 2025. This marks a significant increase in losses compared to the previous quarter's loss of Rs 10.55 lakhs.

Financial Performance

The company's financial results, which were reviewed by the Audit Committee and approved by the Board of Directors on November 12, 2025, reveal a challenging quarter for Auro Laboratories. Here's a breakdown of the key financial metrics:

Despite a significant increase in revenue from operations, rising from Rs 217.42 lakhs in the previous quarter to Rs 883.67 lakhs in the current quarter, the company's expenses also saw a substantial rise. This led to the reported loss for the quarter.

Balance Sheet Highlights

As of September 30, 2025, Auro Laboratories reported:

• Total Assets: Rs 11,077.34 lakhs
• Total Equity: Rs 4,357.84 lakhs
• Non-Current Liabilities: Rs 3,841.97 lakhs
• Current Liabilities: Rs 2,877.53 lakhs

Operational Update

In a separate announcement, Auro Laboratories informed that it has successfully completed a World Health Organization (WHO) inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility located in MIDC Tarapur, Maharashtra. The company has received a World Health Organization - Good Manufacturing Practices (WHO - GMP) Certificate from the Food & Drug Administration, Maharashtra, valid until September 30, 2028.

Investor Considerations

While the company has faced a challenging quarter, the recent WHO-GMP certification could be a positive development for future business prospects. However, it's important to monitor how the company manages its expenses and improves profitability in the coming quarters.

The full financial results are available on the BSE website ( www.bseindia.com ) and the company's website ( www.aurolabs.com ) for further detailed analysis.

Auro Laboratories Ltd, a pharmaceutical company, has announced significant changes in its management structure and auditing arrangements following a board meeting held on August 23, 2025.

New Statutory Auditors Appointed

The company's board has approved the resignation of M/s Kothari Jain & Associates, Chartered Accountants, as Statutory Auditors, effective August 23, 2025. The outgoing auditors cited pre-occupation with other personal and professional commitments as the reason for their departure. They confirmed that there were no disputes or concerns regarding information suppression by the company's management.

To fill this vacancy, the board has appointed M/s B.L. Dasharda & Associates, Chartered Accountants, as the new Statutory Auditors. This appointment is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The new auditors will serve for a period of five years, from the conclusion of the 36th AGM until the 41st AGM.

Re-appointment of Independent Director

Mrs. Kavita Vijayakant Sharma has been re-appointed as a Non-Executive Independent Director for a second term of five years. Her new term will run from February 11, 2026, to February 10, 2031, subject to shareholder approval at the forthcoming AGM. Mrs. Sharma, who has been associated with Auro Laboratories since March 27, 2015, brings over 10 years of experience in marketing to her role.

New Company Secretary and Compliance Officer

The board has appointed Ms. Padma Tapariya as the new Company Secretary and Compliance Officer, effective October 1, 2025. Ms. Tapariya is an associate member of the Institute of Company Secretaries of India (ICSI) and has approximately seven years of experience in her field.

Secretarial Auditors Appointed

M/s GMJ & Associates, Company Secretaries, have been appointed as the Secretarial Auditors of Auro Laboratories for a term of five years, from April 1, 2025, to March 31, 2030. This appointment is also subject to shareholder approval at the upcoming AGM. GMJ & Associates brings over a decade of experience in secretarial audit services across various sectors.

Upcoming Annual General Meeting

Auro Laboratories has scheduled its 36th Annual General Meeting for September 25, 2025. The meeting will be conducted through Video-Conferencing (VC) and Other Audio-Visual Means (OAVM).

These changes reflect Auro Laboratories' commitment to maintaining strong corporate governance practices and ensuring compliance with regulatory requirements. The company's proactive approach in appointing new auditors and key personnel demonstrates its focus on transparency and professional management.